Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RHA 3 is a **gel implant (dermal filler)** consisting of cross-linked **hyaluronic acid**, stabilized with 1,4-butanediol diglycidyl ether and containing 0.3% lidocaine to minimize injection pain. It is injected into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds, and is also indicated for lip augmentation and enhancing lip fullness in adults. The hyaluronic acid is designed to be resilient and adapt to dynamic facial movements, providing natural-looking and long-lasting results, typically lasting up to 12–15 months. The filler is manufactured using technology that preserves the natural properties of hyaluronic acid, allowing for flexibility and strength in areas of frequent movement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RHA 3.